Model for end‐stage liver disease exceptions in the context of the french model for end‐stage liver disease score–based liver allocation system

Claire Francoz, Jacques Belghiti, Denis Castaing, Olivier Chazouillères, Jean‐Charles Duclos‐Vallée, Christophe Duvoux, Jan Lerut, Yves‐Patrice Le Treut, Richard Moreau, Ameet Mandot, Georges Pageaux, Didier Samuel, Dominique Thabut, Dominique Valla, François Durand – 21 June 2011 – Model for End‐Stage Liver Disease (MELD) score–based allocation systems have been adopted by most countries in Europe and North America. Indeed, the MELD score is a robust marker of early mortality for patients with cirrhosis.

Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients

Caroline Barau, Aurélie Barrail‐Tran, Bogdan Hemerziu, Dalila Habes, Anne‐Marie Taburet, Dominique Debray, Valérie Furlan – 21 June 2011 – Mycophenolate mofetil (MMF) is now commonly used in pediatric liver transplant recipients, but no clear recommendations about the dosing regimen have been made for this population. The aim of this study was to determine the MMF dosage required for pediatric liver transplant recipients to achieve an area under the plasma concentration–time curve from 0 to 12 hours (AUC0‐12) for mycophenolic acid (MPA) greater than 30 mg hour/L.

Aldo‐keto reductase‐7A protects liver cells and tissues from acetaminophen‐induced oxidative stress and hepatotoxicity

Munzir M.E. Ahmed, Tao Wang, Yu Luo, Shuilong Ye, Qiao Wu, Zongsheng Guo, Bill D. Roebuck, Thomas R. Sutter, James Y. Yang – 17 June 2011 – Aldo‐keto reductase‐7A (AKR7A) is an enzyme important for bioactivation and biodetoxification. Previous studies suggested that Akr7a might be transcriptionally regulated by oxidative stress‐responsive transcription factor nuclear factor erythroid 2 p45‐related factor 2 (Nrf2), a protein highly responsive to acetaminophen (APAP) or its intermediate metabolite, N‐acetyl‐p‐benzoquinoneimine (NAPQI).

Subscribe to